Rabbit anti-p53 Antibody, Affinity Purified
SIGMA/PLA0072
Synonym: BCC7; LFS1; Li-Fraumeni syndrome; TRP53; Tumor suppressor p53; antigen NY-CO-13; mutant tumor protein 53; p53; p53 tumor suppressor; phosphoprotein p53; transformation-
Product Type: Product-on-demand
Immunohistochemistry Rabbit Anti-p53 Antibody, Affinity Purified: Cat. No. PLA0072: Detection of Human p53 by Immunohistochemistry. Sample: FFPE section of Human skin carcinoma. Antibody: Affinity purified Rabbit Anti-p53 (Cat. No. PLA0072) used at a dilution of 1:1,000 (1 μg/mL). Detection: DAB
Western Blotting Rabbit Anti-p53 Antibody, Affinity Purified: Cat. No. PLA0072: Detection of Human p53 by Western Blot. Samples: Whole cell lysate (100 μg) from 293T cells that were treated with an siRNA for p53 (+) or mock treated (-). Antibody: Rabbit Anti-p53 Antibody (Cat. No. PLA0072) used at the indicated concentrations. Detection: Chemiluminescence with an exposure time of less than 1 minute.
Flow Cytometry Rabbit Anti-p53 Antibody, Affinity Purified: Cat. No. PLA0072: Flow Cytometrical Analysis of p53 in Jurkat Cells. Jurkat cells were fixed in 1.5% PFA, and permeabilized in 90% Methanol. 1 × 106 cells were stained with 1.5 μg Anti-KLH IgG control or Anti-p53 (PLA0072) and secondary FITC-conjugated goat Anti-Rabbit (in a 150 μl reaction). Anti-KLH control IgG (black); Anti-p53 (red).
| accession no. | P04637 |
| antibody form | affinity purified immunoglobulin |
| antibody product type | primary antibodies |
| biological source | rabbit |
| clone | polyclonal |
| conjugate | unconjugated |
| Quality Level | 100  |
| shipped in | wet ice |
| species reactivity | human |
| storage temp. | 2-8°C |
| target post-translational modification | unmodified |
| technique(s) | ChIP: 4-30 μg |
| flow cytometry: 1.5 μg | |
| immunohistochemistry: 1:1,000- 1:5,000 | |
| immunoprecipitation (IP): 2-5 μg/mg | |
| western blot: 1:2,000-1:10,000 |
| Biochem/physiol Actions: | Tumor suppressor p53 has an ability to induce cell cycle arrest. It also plays a key role in DNA repair, senescence and apoptosis. It binds to simian vacuolating virus 40 (SV40) T-antigen and human papilloma virus E6 protein. Mutation in the p53 gene is associated with the development of various types of cancers, such as breast, ovarian, bladder, colon and lung cancer. |
| Disclaimer: | Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals. |
| General description: | p53, also known as transformation related protein 53 (TRP53), is encoded by the gene mapped to human chromosome 17p13.1. p53 is a tumor suppressor gene expressed in a wide variety of tissues. The gene codes for a tetrameric nuclear DNA-binding phosphoprotein. |
| Immunogen: | The epitope recognized by PLA0072 maps to a region between residues 50 and 100 of human tumor protein p53 using the numbering given in SwissProt entry P04637 (GeneID 7157). |
| Other Notes: | p53 is a tumor suppressor protein that is mutated or inactivated in over 50% of human cancers. Loss of function defects in p53 are the cause of the autosomal dominant familial cancer syndrome, Li-Fraumeni syndrome (LFS) that is characterized by the development of a diverse set of malignancies at very early ages. At the cellular level p53 is involved in the negative regulation of cell the cycle via its transactivational control of genes required for cell cycle progression. Depending on the physiological circumstance, p53 can promote growth arrest or apoptosis. |
| Physical form: | Tris-citrate/phosphate buffer, pH 7 to 8 containing 0.09% sodium azide |
| RIDADR | NONH for all modes of transport |
| WGK Germany | nwg |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352203 |